Showing 701-710 of 1942 results for "".
Breaking News from the ASCRS Meeting in Los Angeles
https://modernod.com/podcasts/eyewire-news-the-podcast/breaking-news-from-the-ascrs-meeting-in-los-angeles/37082/EyewireTV reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles. Learn more about your ad choices. Visit megaphone.fm/adchoicesAlcon Voyager DSLT Fully Launched in US
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-voyager-dslt-fully-launched-in-us/37072/Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System. Learn more about your ad choices. Visit megaphone.fm/adchoicesAAO Opposes NIH Research Funding Proposal
https://modernod.com/podcasts/eyewire-news-the-podcast/aao-opposes-nih-research-funding-proposal/37071/The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system. Learn more about your ad choices. Visit megaphone.fmSpecial Report – Increasing Access to Care Through the Cure Blindness Project
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-increasing-access-to-care-through-the-cure-blindness-project/37067/Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world. Learn more about your ad choices. Visit megaphone.fm/adchoicesB+L Bolsters Glaucoma Offerings with Elios Acquisition
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-bolsters-glaucoma-offerings-with-elios-acquisition/37063/Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices. Learn more about your ad choices. Visit megaphone.fm/adchoicesFirst Commerical Surgeries Performed with MacTel Therapy
https://modernod.com/podcasts/eyewire-news-the-podcast/first-commerical-surgeries-performed-with-mactel-therapy/37097/Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad chTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesSpecial Report: Executives Discuss Overcoming Challenges
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-executives-discuss-overcoming-challenges/37086/Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge. Learn more about your ad choices. Visit megaphone.fm/adchoicesUtilizing AI to Provide DR Screening to Underserved Communities
https://modernod.com/podcasts/eyewire-news-the-podcast/utilizing-ai-to-provide-dr-screening-to-underserved-communities/37079/EyewireTV speaks with the leaders of Digital Diagnostics and AEYE Health about their diabetic screening technology, racial and socioeconomic disparities in eye care, and their mission to improve health equity by expanding their technology into underserved populations. Learn more about your ad choiceAlcon Launches PanOptix Pro in US
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-launches-panoptix-pro-in-us/37078/Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform. Learn more about your ad choices. Visit megaphone.fm/adchoices